Reata Stock Analysis


USD 39.35  0.23  0.58%   

The current price rise of Reata Pharmaceuticals created some momentum for investors as it was traded today as low as 39.01 and as high as 40.68 per share. The company directors and management may have good odds in positioning the company resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.46. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Reata Pharmaceuticals partners.
Additionally, take a look at Your Equity Center.
The Reata Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Reata Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Reata Stock analysis module also helps to analyze the Reata Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Reata Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 8.35. Reata Pharmaceuticals had not issued any dividends in recent years. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. To find out more about Reata Pharmaceuticals contact Warren Huff at 972 865 2219 or learn more at

Reata Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Reata Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Reata Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Reata Pharmaceuticals is way too risky over 90 days horizon
Reata Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 11.49 M. Net Loss for the year was (297.39 M) with loss before overhead, payroll, taxes, and interest of (144.5 M).
Reata Pharmaceuticals currently holds about 481.47 M in cash with (235.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.19.
Reata Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 89.0% of the company shares are owned by institutional investors
Latest headline from Citigroup Adjusts Price Target on Reata Pharmaceuticals to 53 From 51, Maintains Buy Rating -

Reata Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Reata Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Reata Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Reata Largest EPS Surprises

Earnings surprises can significantly impact Reata Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Reata Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Reata Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Reata Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Reata Profitablity

Reata Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Reata Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Reata Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Reata Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Reata Pharmaceuticals' profitability requires more research than a typical breakdown of Reata Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(81.11) (87.51) 
Return on Average Assets(37.35) (40.29) 
Return on Average Equity(98.57) (106.35) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2566) % which means that it has lost $0.2566 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.3938) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals management efficiency ratios could be used to measure how well reata pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2022, Return on Investment is expected to decline to -87.51. In addition to that, Return on Average Assets is expected to decline to -40.29. Reata Pharmaceuticals Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 735.02 Million. The current year Current Assets is expected to grow to about 643.6 M, whereas Net Current Assets as percentage of Total Assets are forecasted to decline to 63.34.

Technical Drivers

As of the 1st of December, Reata Pharmaceuticals holds the Coefficient Of Variation of 678.62, semi deviation of 3.79, and Risk Adjusted Performance of 0.2271. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Reata Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Reata Pharmaceuticals, which can be compared to its competitors. Please check Reata Pharmaceuticals treynor ratio, and the relationship between the standard deviation and downside variance to decide if Reata Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 39.35 per share. Given that Reata Pharmaceuticals has jensen alpha of 0.8709, we recommend you to check out Reata Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Reata Pharmaceuticals Price Movement Analysis

The output start index for this execution was eighteen with a total number of output elements of fourty-three. Reata Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of Reata Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

Reata Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Reata Pharmaceuticals Predictive Daily Indicators

Reata Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Reata Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Reata Pharmaceuticals Forecast Models

Reata Pharmaceuticals time-series forecasting models is one of many Reata Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Reata Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Reata Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Reata Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Reata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Reata Pharmaceuticals. By using and applying Reata Stock analysis, traders can create a robust methodology for identifying Reata entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(112.26) (115.21) 
EBITDA Margin(109.54) (112.42) 
Profit Margin(114.07) (117.07) 

Current Reata Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Reata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Reata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Reata Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Reata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Reata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Reata Pharmaceuticals, talking to its executives and customers, or listening to Reata conference calls.
Reata Analyst Advice Details

Reata Stock Analysis Indicators

Reata Pharmaceuticals stock analysis indicators help investors evaluate how Reata Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Reata Pharmaceuticals shares will generate the highest return on investment. By understating and applying Reata Pharmaceuticals stock analysis, traders can identify Reata Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow818150000.00
Logo U R LimglogosUSRETA.png
Common Stock Shares Outstanding36321351.00
Total Stockholder Equity185989000.00
DescriptionReata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bar
Total Cashflows From Investing Activities-1329000.00
Tax Provision-450000.00
Property Plant And Equipment Net138381000.00
Retained Earnings-1255631000.00
Cash And Short Term Investments590258000.00
Retained Earnings Total Equity-1255631000.00
Accounts Payable13505000.00
Net Debt-454225000.00
50 Day M A31.5674
Total Current Liabilities53994000.00
Currency CodeUSD
Other Operating Expenses256198000.00
Non Current Assets Total138541000.00
Common Stock Total Equity36000.00
Non Currrent Assets Other160000.00
Additionally, take a look at Your Equity Center. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running Reata Pharmaceuticals price analysis, check to measure Reata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reata Pharmaceuticals is operating at the current time. Most of Reata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reata Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Reata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Reata Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reata Pharmaceuticals. If investors know Reata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reata Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.5 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Reata Pharmaceuticals is measured differently than its book value, which is the value of Reata that is recorded on the company's balance sheet. Investors also form their own opinion of Reata Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reata Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reata Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Reata Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.